10

Loading video...

Andrew Gould

By Andrew Gould

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


The Texas Rangers will hope to avoid losing another starting pitcher after Jacob deGrom's last start ended early.

DeGrom threw 53 pitches over two innings before exiting due to right triceps fatigue. He allowed six hits and two runs in Thursday's 7-0 loss to the Los Angeles Angels.

After the game, deGrom expressed optimism that the setback wouldn't force him to miss any time.

Read More on MLB

"I'm not too concerned," deGrom said, per MLB.com's Jacob Gurvis. "Hopefully I'll make my next (start). We'll see. Tonight, it just -- there in the second it was tight and just didn't want to loosen up. I haven't really had that before."

The 38-year-old is expected to undergo imaging on Friday to determine the issue's severity. While the two-time Cy Young Award winner felt he could have kept pitching, Rangers manager Skip Schumaker didn't want to take any chances.

Texas Rangers starting pitcher Jacob deGrom

...

"Just see how it is tomorrow and then come up with a plan," deGrom said on Thursday night. "We've been doing a lot to treat that area. That's what I normally do in my routine. But this last, whatever, week, I guess, it just didn't recover, and then I felt it tonight there in the second. They made the decision that it was not best to go forward."

Injuries limited deGrom to just nine starts in his first two seasons with the Rangers, but he rebounded to post a 2.97 ERA and 0.92 WHIP in 30 starts last year. The right-hander's ERA rose to 3.95 in 120.2 innings following Thursday's abbreviated outing.

Losing deGrom for any amount of time would be a tough blow for the Rangers, who placed fellow veteran starter Nathan Eovaldi on the 15-day injured list with elbow inflammation earlier this week. Cody Bradford recently returned from elbow surgery, and Jack Leiter began a rehab assignment on Thursday.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines